The US FDA has accepted to review Bristol-Myers Squibb Company and Pfizer's Eliquis (apixaban) supplemental new drug application for prophylaxis of deep vein thrombosis (DVT) subsequent to hip or knee replacement surgery. The application ...
Tags: Drug Application, Medicine
Bristol-Myers Squibb and Simcere Pharmaceutical Group have extended their collaboration to develop and commercialize the subcutaneous (SC) formulation of Bristol-Myers Squibb's biologic medicine, Orencia (abatacept), in China. Orencia was ...
Tags: Bristol-Myers Squibb, Medicine
The USFDA has granted priority review designation for investigational agent Metreleptin, jointly developed by Bristol-Myers Squibb Company and AstraZeneca, for the treatment of metabolic disorders associated with rare forms of ...
The US Food and Drug Administration (FDA) has approved labeling changes to Bristol-Myers Squibb's Reyataz (atazanavir), an antiretroviral medication. The label will now include warnings about kidney and gall stones in addition to updated ...
Bristol-Myers Squibb has reached an agreement with Reckitt Bencksier for several of its over-the-counter medicines. As part of the agreement, Reckitt Benckiser will pay Bristol-Myers Squibb $438 million (£282 million) upfront for ...
UK-based pharmaceutical company Bristol-Myers Squibb and AstraZeneca have announced that the National Institute for Health and Clinical Excellence (NICE) in the UK has issued an Appraisal Consultation Document (ACD) for its first-in-class, ...
Tags: pharmaceutical company, Bristol-Myers Squibb, AstraZeneca, NICE
Tranzyme Pharma has completed the chemistry-based drug discovery partnership and transferred the resulting compounds to Bristol-Myers Squibb to advance the development. The strategic collaboration leveraged Macrocyclic Template Chemistry, ...
Tags: Tranzyme Pharma, chemistry based drug, chemistry technology, company news
Bristol-Myers Squibb and Pfizer have announced the US FDA's approval for Eliquis (apixaban), used to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation. In 2007, Pfizer and Bristol-Myers ...
Tags: US, FDA, Eliquis, patients, nonvalvular atrial fibrillation
Bristol-Myers Squibb and Pfizer have announced the approval of Eliquis (apixaban) anticoagulant for the prevention of ischemic stroke and systemic embolism in patients suffering from nonvalvular atrial fibrillation (NVAF) in Japan. The ...
Tags: Japan, approval, anticoagulant, subanalysis
Bristol-Myers Squibb will acquire Amylin for $31.00 per share in cash, pursuant to a cash tender offer and second step merger, or a total buying price nearing $5.3bn. The acquisition value includes Amylin's debt proceeds and a contractual ...
Synergy Pharmaceuticals has signed an asset purchase agreement to acquire FV-100 shingles drug from Bristol-Myers Squibb Company. FV-100 is an orally available nucleoside analogue, at present being developed for the treatment of shingles, ...
Tags: Synergy Pharmaceuticals, treatment of shingles, FV-100
New York College of Health Professions doesn't have a sports team, but it is about to make sports history with the development of a new line of functional acupressure clothing and accessories called MyChi. The line, which can help athletes ...
Tags: acupressure clothing, health, clothing line
Prosetta Antiviral has entered into a multi-year collaboration with Bristol-Myers Squibb Company to further discover and develop select drug candidates representing new, novel classes of antiviral drugs. The collaboration will focus on ...
Prosetta Antiviral has entered into a multi-year collaboration with Bristol-Myers Squibb Company to further discover and develop select drug candidates representing new, novel classes of antiviral drugs. The collaboration will focus on ...
Tags: lect drug candidates, antiviral drugs, viral infections
Bristol-Myers Squibb, a biopharmaceutical company, has terminated the development of BMS-986094, an investigational NS5B nucleotide for the treatment of hepatitis C. Based on an ongoing assessment of patients in a Phase II study that the ...
Tags: BMS-986094, Bristol-Myers, hepatitis C, NS5B nucleotide